Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nanjing Leads Biolabs Co Ltd (9887.HK)
Nanjing, CN
Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the clinical development phase, dedicated to the global discovery, progression, and eventual market launch of innovative antibody-based medications. The company's therapeutic endeavors concentrate on various critical illnesses, including cancerous growths, autoimmune disorders, and other serious medical conditions. A prominent product in its development pipeline is LBL-024, a bispecific antibody engineered to target PD-L1 and 4-1BB, specifically for the treatment of extra-pulmonary neuroendocrine carcinoma. Other significant compounds under development include LBL-034, LBL-033, and LBL-007. Nanjing Leads Biolabs also leverages its proprietary LeadsBody platform, which focuses on CD3 T-cell engagers that have demonstrated promising anti-tumor effects and safety in preliminary studies, as well as the X-body platform, which specializes in 4-1BB/PD-L1 bispecific antibodies. Beyond these, the company is actively researching antibody treatments for oncological, autoimmune, and infectious diseases, and is also engaged in establishing tumor immunoassays. Established in 2012, its primary operations are based in Nanjing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.41% | -5.69% | -28.51% | -13.20% | +1.22% | +5.69% | -19.67% | -19.67% | -19.67% | -19.67% | -19.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-365.5% Q4'25: +69.0% (vs Q4'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-119.0% Q4'25: +0.0% (vs Q4'24)
-
EBIT margin Biotechnology: +0.0%-109.8% Q4'25: -15.2% (vs Q4'24)
-
ROIC Biotechnology: -16.1%— Q4'25: +3,222.6% (vs Q4'24)
-
Share dilution Biotechnology: -3.4%+16.1% Q4'25: +25.7% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.41× Q4'25: -7.35× (vs Q4'24)
| Metric |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 4 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
197.20M
est: 194.75M (+1.3%)
|
245.63M
148.49M – 334.11M
+26.1% YoY
|
521.21M
198.19M – 972.37M
+112.2% YoY
|
750.24M
334.22M – 1.29B
+43.9% YoY
|
6.34B
2.83B – 10.90B
+745.7% YoY
|
| EBITDA |
-199.03M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-216.42M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-235.21M
est: -240.32M (+2.1%)
|
-225.38M
-250.76M – -199.99M
+6.2% YoY
|
-49.39M
-49.70M – -49.07M
+78.1% YoY
|
-201.10M
-388.96M – -56.14M
-307.2% YoY
|
1.35B
376.58M – 2.61B
+770.8% YoY
|
| SGA |
92.01M
est: 329.05M (-72.0%)
|
415.02M
250.89M – 564.51M
+26.1% YoY
|
880.63M
334.86M – 1.64B
+112.2% YoY
|
1.27B
564.70M – 2.18B
+43.9% YoY
|
10.72B
4.78B – 18.42B
+745.7% YoY
|
| EPS |
-1.35
est: -1.38 (+2.2%)
|
-1.29
-1.44 – -1.15
+6.2% YoY
|
-0.28
-0.29 – -0.28
+78.1% YoY
|
-1.15
-2.23 – -0.32
-307.2% YoY
|
7.75
2.16 – 14.98
+770.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-10 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-09 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-03 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.13% | 86.3K | 0.59% |
| 2 | UBS Solactive China Technology UCITS ETF USD acc CQQQ.SW | 0.10% | 364.5K | 0.47% |
| 3 | UBS Solactive China Technology UCITS ETF hEUR acc CITE.MI | 0.10% | 362.5K | 0.50% |
| 4 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.02% | 12.1K | 0.74% |
| 5 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.01% | 38.8K | 0.74% |
| 6 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.01% | 58.6K | 0.55% |
| 7 | iShares Core MSCI EM IMI UCITS ETF EIMI.L | 0.00% | 425.5K | 0.18% |
| 8 | iShares Core MSCI EM IMI UCITS ETF EIMU.L | 0.00% | 17.5K | 0.18% |
| 9 | State Street SPDR Portfolio MSCI Global Stock Market ETF SPGM | 0.00% | 10.8K | 0.09% |
| 10 | iShares Core MSCI Emerging Markets ETF IEMG | 0.00% | 710.6K | 0.09% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Honggang Zuo | CFO, Joint Company Secretary & Executive Director | 5M | male |
| Xiaoqiang Kang | Co-Founder, Executive Chairman, GM & Chief Executive Officer | 5M | — |
| Shoupeng Lai | Co-Founder, Chief Strategic Officer, Executive Vice President & Executive Director | 1M | — |
| Xuegen Jian | Joint Company Secretary | — | female |
| Shengli Cai | Chief Medical Officer | — | — |
| Qing-lai Zhu | Vice President & Head of Global Business Development | — | male |
| Hong Ling | Senior Vice President & Chief Scientific Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9887.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
